AGMB
AgomAb Therapeutics NV
NASDAQ · Healthcare · Biotechnology · BE
$12.17
+0.75%Institutional positioning
13F filings over the trailing two quarters
New 41Increased 4Reduced 6Sold out 7
| Filer | Action | Shares | Filed |
|---|---|---|---|
| EQT Fund Management S.a r.l. | Unchanged | 5,141,992 | Aug 13, 2026 |
| EQT FUND MANAGEMENT S.A R.L. | New Position | 5,141,992 | May 14, 2026 |
| Sanofi | Unchanged | 2,783,096 | Jul 28, 2026 |
| SANOFI | New Position | 2,783,096 | May 7, 2026 |
| Redmile Group, LLC | Increased | 2,733,926 | Aug 14, 2026 |
| CORMORANT ASSET MANAGEMENT, LP | New Position | 2,465,348 | May 15, 2026 |
| Cormorant Asset Management, LP | Unchanged | 2,465,348 | Aug 14, 2026 |
| TCG CROSSOVER MANAGEMENT, LLC | New Position | 2,053,233 | May 15, 2026 |
| TCG Crossover Management, LLC | Unchanged | 2,053,233 | Aug 14, 2026 |
| FEDERATED HERMES, INC. | Unchanged | 1,618,000 | Aug 12, 2026 |
| FEDERATED HERMES, INC. | New Position | 1,618,000 | May 11, 2026 |
| Nantahala Capital Management, LLC | Increased | 1,568,188 | Aug 19, 2026 |
| CASDIN CAPITAL, LLC | New Position | 1,550,000 | May 15, 2026 |
| Casdin Capital, LLC | Unchanged | 1,550,000 | Aug 14, 2026 |
| Andera Partners | Unchanged | 1,538,702 | Jul 22, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings